GlassScriptPhysician profile
Sarhad David Najor
NPI 1558802769
$9,336.82
in general payments reported to CMS, 2019-2025
58 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.66 · 2021: $854 · 2022: $1,751 · 2023: $2,188 · 2024: $2,252 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,700 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,699.55 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,093.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,031.62 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $811.94 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $631.74 | 2021-2025 | |
| Pfizer INC. | $516.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $463.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $385.03 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $332.80 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $323.97 | 2022-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.36 | 2021-2025 | Xifaxan |
| Amgen INC. | $280.11 | 2021-2025 | Krystexxa, Repatha, Enbrel |
| Otsuka America Pharmaceutical, INC. | $251.82 | 2022-2025 | Rexulti |
| Corcept Therapeutics | $221.15 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.40 | 2021-2024 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $175.91 | 2021-2024 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $174.02 | 2021-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.18 | 2024-2025 | Caplyta |
| Horizon Therapeutics Plc | $141.50 | 2021 | |
| Sumitomo Pharma America, INC. | $137.97 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $137.14 | 2023-2025 | Sunosi, Auvelity |
| Sanofi-Aventis U.S. LLC | $136.85 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.82 | 2022-2024 | Trintellix |
| Aimmune Therapeutics, INC. | $110.20 | 2024-2025 | Zenpep, Vowst |
| Biohaven Pharmaceutical Holding Company LTD. | $108.20 | 2022 | |
| Astellas Pharma US INC | $101.27 | 2024-2025 | Veozah |
| Dexcom, INC. | $83.06 | 2022-2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $74.35 | 2025 | Nayzilam |
| Amarin Pharma, INC. | $67.11 | 2021-2022 | |
| Exact Sciences Corporation | $62.69 | 2023-2025 | Cologuard Collection Kit |
| Inari Medical, INC. | $42.23 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Neurocrine Biosciences, INC. | $40.05 | 2021-2024 | Ingrezza |
| Mylan Specialty L.P. | $39.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $38.13 | 2024-2025 | Voquezna |
| Krystal Biotech INC | $37.38 | 2025 | Vyjuvek |
| Shield Therapeutics INC | $36.16 | 2023 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $34.03 | 2021 | |
| United Therapeutics Corporation | $33.54 | 2025 | Tyvaso |
| Seqirus USA INC | $32.25 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Lexicon Pharmaceuticals, INC. | $30.64 | 2023-2024 | Inpefa |
| Cequr Corporation | $30.45 | 2024-2025 | Cequr Simplicity |
| Genentech USA, INC. | $28.68 | 2019-2021 | |
| Abbott Laboratories | $24.06 | 2022 | |
| Sage Therapeutics, LLC | $21.03 | 2025 | Zurzuvae |
| Genzyme Corporation | $20.35 | 2024 | |
| Nestle Healthcare Nutrition INC. | $19.31 | 2023 | |
| Cmp Pharma, INC. | $18.77 | 2022 | |
| Ibsa Pharma INC. | $17.81 | 2022 | |
| Alkermes, INC. | $17.68 | 2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $17.66 | 2023 | Belbuca |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Averitas Pharma INC. | $17.33 | 2024 | Qutenza |
| Edwards Lifesciences Corporation | $17.02 | 2021 | |
| Antares Pharma, INC. | $15.21 | 2025 | Xyosted |
| Verona Pharma, INC. | $15.20 | 2025 | Ohtuvayre |
| Biogen, INC. | $14.60 | 2022 | |
| Bioventus LLC | $13.44 | 2023 | Durolane |
| Abiomed | $13.36 | 2023 | Impella |
| Grt US Holding, INC. | $8.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarhad Najor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.